Active Ingredient History
Epirubicin is an anthracycline cytotoxic agent, is a 4'-epi-isomer of doxorubicin. The compound is marketed by Pfizer under the trade name Ellence in the US. It is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. Although it is known that anthracyclines can interfere with a number of biochemical and biological functions within eukaryotic cells, the precise mechanisms of epirubicin’s cytotoxic and/or antiproliferative properties have not been completely elucidated. It is known, that epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also inhibits DNA helicase activity, preventing the enzymatic separation of double-stranded DNA and interfering with replication and transcription. Epirubicin is also involved in oxidation/reduction reactions by generating cytotoxic free radicals. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 3)
Anterior Cruciate Ligament Injuries (Phase 2)
Bile Duct Neoplasms (Phase 1/Phase 2)
BRCA1 Protein (Phase 2)
Breast Carcinoma In Situ (Phase 2)
Breast Diseases (Phase 2/Phase 3)
Breast Neoplasms, Male (Phase 1)
Carcinoma (Phase 3)
Carcinoma, Hepatocellular (Phase 4)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Cardiotoxicity (Phase 3)
Chemotherapy, Adjuvant (Phase 3)
Down Syndrome (Phase 2)
Drug Therapy (Phase 3)
Endometrial Neoplasms (Phase 3)
Enteropathy-Associated T-Cell Lymphoma (Phase 4)
Esophageal Neoplasms (Phase 3)
Fallopian Tube Neoplasms (Phase 3)
Febrile Neutropenia (Phase 2)
Gallbladder Neoplasms (Phase 3)
Geriatrics (Phase 3)
Hamartoma (Phase 3)
Head and Neck Neoplasms (Phase 1/Phase 2)
Hearing Disorders (Phase 1/Phase 2)
Hodgkin Disease (Phase 2)
Inflammatory Breast Neoplasms (Phase 3)
Intestinal Neoplasms (Phase 2)
Leukemia (Phase 2)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 4)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 4)
Lymphoma, Large-Cell, Anaplastic (Phase 4)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Non-Hodgkin (Phase 4)
Lymphoma, T-Cell (Phase 4)
Lymphoma, T-Cell, Peripheral (Phase 2)
Melanoma (Phase 2)
Mesothelioma, Malignant (Phase 2)
Multiple Myeloma (Phase 4)
Mutation (Phase 2)
Nasopharyngeal Carcinoma (Phase 3)
Neoadjuvant Therapy (Phase 2/Phase 3)
Neoplasm Metastasis (Phase 3)
Neoplasms ()
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neoplastic Cells, Circulating (Phase 4)
Neutropenia (Phase 2)
Ovarian Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 2/Phase 3)
Pathology (Phase 2/Phase 3)
Pediatrics (Phase 3)
Postoperative Complications (Phase 3)
Prognosis (Phase 2)
Prostatic Neoplasms (Phase 2)
ras Proteins (Phase 2)
Rhabdomyosarcoma (Phase 3)
Safety (Phase 2)
Sarcoma (Phase 3)
Sepsis (Phase 2)
Small Cell Lung Carcinoma (Phase 3)
Stomach Neoplasms (Phase 3)
Testicular Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 3)
Ureteral Neoplasms (Phase 2)
Urinary Bladder Diseases (Phase 2)
Urinary Bladder Neoplasms (Phase 4)
Wilms Tumor (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
